Founded by internationally-recognized dermatologist, Dr. Jason Rivers, Riversol skin care products are developed in Vancouver and sold throughout North America. The signature brand of Pacific Dermaesthetics. Riversol delivers superior quality and proven results.

While searching for a skin care line for patients with extremely sensitive skin, Dr. Rivers became aware of thujaplicin, a potent antioxidant derived from the Pacific Red Cedar tree. Clinical studies had demonstrated thujaplicin to have anti-inflammatory, antibiotic, antifungal and healing properties – and very effective for sensitive and rosacea skin care.

Features & Benefits

Riversol formulations combine thujaplicin with stabilized Vitamin C and Vitamin E; and contain no fragrances, dyes or sulphates. After using Riversol skin care products, patients with rosacea have experienced fewer or no flare-ups, while patients with anti-aging skin needs (sun damage, premature aging) have seen visible improvement over time.

Other Benefits of Riversol:

  • Oily skin – effectively controls oil production while providing hydration
  • Mattifying system – provides long-lasting hydration without residual greasiness
  • Antioxidants – even out skin tone, texture & reduce sun damage
  • Gentle cleansers – remove impurities without disrupting your skin’s mantle (which protects the skin from contaminants)
  • Calming serums – deep-healing formulations reduce redness and imperfections
  • Minimum allergy risk  – do not contain dyes, sulphates or fragrances

Skin Type Match

Riversol skin care products are appropriate for:

  • Rosacea skin and redness
  • Acne skin
  • Highly sensitive skin
  • Mature skin
  • Dry skin
  • Oily skin
  • Normal skin

Contact us to purchase Riversol or to make an appointment with one of our skin care team members to learn more.

Be in the know.

Get insider tips, offers and valuable skin care information from our experts.

Privacy Policy

Clinical Studies Contact Form

I am interested in the following area of study:


Yes, contact me for future clinical studies